Philippe E. Spiess, MD, MS, FACS, assistant chief of Surgical Services, senior member, Department of Genitourinary Oncology, Moffitt Cancer Center; and professor of oncology and urology, Department of Urology, University of South Florida Morsani College of Medicine, shares key updates in the management of patients with penile cancer.

Early diagnosis remains a key factor in the care of patients with penile cancer, Spiess says. Previously, the majority of patients diagnosed with this disease would undergo radical surgery, which could lead to depression due to a loss of sexual function and quality of life (QOL), Spiess explains.

Penile-sparing surgical approaches have emerged as an alternative to radical procedures, allowing patients to maintain sexual function, improve QOL, and achieve better outcomes, Spiess adds.

For patients with advanced disease that has spread to the lymph nodes, a multimodal approach to treatment is beneficial, Spiess says. Consulting with medical and radiation oncologists can help to tailor management plans to each patient, Spiess concludes.

Videos

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Dr. Spiess on Key Updates in the Management of Penile Cancer

Philippe E. Spiess, MD, MS, FACS, genitourinary oncologist, assistant chief, Surgical Services, Moffitt Cancer Center, full professor of Oncology, Urology, the University of South Florida, Morsani College of Medicine, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

Though there are several options for initial treatment in genitourinary cancers, including prostate cancer, bladder cancer, and kidney cancer, limited resources exist beyond those therapies if patients do not respond, Spiess says. To address these needs, researchers have come to understand some of the genetic and biological pathways in these cancers, including the MTAP pathway, which specifically plays a role in carcinogenesis, Spiess adds.

Research aimed to investigate difficult-to-treat subsets of cancers by better understanding the importance of 

 deletions, Spiess continues. Learning how to target this pathway could help the development and use of certain types of novel therapies, Spiess concludes.

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.


Philippe E. Spiess, MD, MS, FACS

Articles

Dr. Spiess on Key Updates in the Management of Penile Cancer

Dr. Spiess on the Rationale for Investigating the MTAP Pathway in Genitourinary Cancers